Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. The company is headquartered in South San Francisco, California and currently employs 128 full-time employees. The company went IPO on 2020-04-24. The firm is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The firm's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Follow-Up Questions
Oric Pharmaceuticals Inc의 CEO는 누구입니까?
Dr. Jacob Chacko은 2018부터 회사에 합류한 Oric Pharmaceuticals Inc의 President입니다.
ORIC 주식의 가격 성능은 어떻습니까?
ORIC의 현재 가격은 $12.3이며, 전 거래일에 increased 0.04% 하였습니다.
Oric Pharmaceuticals Inc의 주요 사업 주제나 업종은 무엇입니까?
Oric Pharmaceuticals Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Oric Pharmaceuticals Inc의 시가총액은 얼마입니까?
Oric Pharmaceuticals Inc의 현재 시가총액은 $1.1B입니다
Oric Pharmaceuticals Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 13명의 분석가가 Oric Pharmaceuticals Inc에 대한 분석 평가를 실시했으며, 이는 9명의 강력한 매수, 8명의 매수, 1명의 보유, 0명의 매도, 그리고 9명의 강력한 매도를 포함합니다
